 |
인쇄하기
취소
|
IP-K, Sanofi Aventis Korea to conduct new research collaboration to combat HBV
Hepatitis B, one of the most common and serious infectious diseases, will be targeted in a new collaborative venture between Institut Pasteur Korea (IP-K) and the Korean arm of the leading global healthcare company, Sanofi-Aventis Korea.
The goal is to develop and validate a high throughput assay to screen IP-K's chemical libraries for novel compounds that can be developed as new drugs.
...
The goal is to develop and validate a high throughput assay to screen IP-K's chemical libraries for novel compounds that can be developed as new drugs.
...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.